Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Circulating inhibitors.

W C Ting

    Annals of the Academy of Medicine, Singapore
    |July 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Circulating inhibitors in non-hemophiliacs caused major bleeding, while low-titre Factor VIIIC antibodies in hemophiliacs were manageable. Treatment options for Factor VIIIC inhibitors include immune tolerance induction and prothrombin complex concentrate.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Ministry of health clinical practice guidelines: clinical blood transfusion.

    Singapore medical journal·2011
    Same author

    Life-threatening coagulopathy associated with use of Campath (alemtuzumab) in maintenance steroid-free renal transplant given before surgery.

    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2008
    Same author

    Massive blood transfusion.

    Singapore medical journal·1991
    Same author

    Polycythaemia after renal transplantation.

    Annals of the Academy of Medicine, Singapore·1987
    Same author

    Evaluation of the common conditions associated with eosinophilia.

    Journal of clinical pathology·1985
    Same author

    Inhibition of erythroid colony growth in vitro by serum from patients with disseminated bronchial cancer.

    Experimental hematology·1984
    Same journal

    "Gazing into the crystal ball of mortality prediction in conservative kidney care": Correspondence.

    Annals of the Academy of Medicine, Singapore·2026
    Same journal

    Vascular stiffness and sepsis mortality: A promising signal in search of clinical relevance.

    Annals of the Academy of Medicine, Singapore·2026
    Same journal

    Transcatheter aortic valve implantation for severe aortic regurgitation with Trilogy system: Initial Southeast Asia experience.

    Annals of the Academy of Medicine, Singapore·2026
    Same journal

    Singapore expert consensus on optimising lipid-lowering strategies in acute coronary syndrome: A modified Delphi study.

    Annals of the Academy of Medicine, Singapore·2026
    Same journal

    Association of estimated pulse wave velocity with 28-day mortality in sepsis: A MIMIC-IV study.

    Annals of the Academy of Medicine, Singapore·2026
    Same journal

    Prognostic value of the monocyte-to-albumin ratio in nasopharyngeal carcinoma: A retrospective cohort study.

    Annals of the Academy of Medicine, Singapore·2026
    See all related articles

    Area of Science:

    • Hematology
    • Immunology

    Background:

    • Factor VIIIC inhibitors can complicate hemophilia management.
    • Non-specific inhibitors and Factor VIIIC antibodies present distinct clinical challenges.

    Purpose of the Study:

    • To analyze the clinical significance of non-specific inhibitors and Factor VIIIC antibodies.
    • To review current treatment strategies for hemophiliacs with Factor VIIIC inhibitors.

    Main Methods:

    • Case series analysis of patients with circulating inhibitors.
    • Review of hemophilia patient data regarding antibody development and management.

    Main Results:

    • Non-specific inhibitors in 13 patients did not cause significant bleeding.
    • Five non-hemophiliacs with Factor VIIIC inhibitors experienced major bleeding.

    Related Experiment Videos

  • 5% of hemophiliacs developed low-titre Factor VIIIC antibodies, posing minimal management issues.

    • Conclusions:

    • Factor VIIIC inhibitors in non-hemophiliacs are associated with severe bleeding.
    • Low-titre Factor VIIIC antibodies in hemophiliacs are generally well-managed.
    • Treatment modalities for Factor VIIIC inhibitors include immune tolerance, prothrombin complex concentrates, and plasmapheresis.